Mark DeLong - Apr 20, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Senior Vice President
Signature
/s/ David Watson, attorney-in-fact for Mark Delong
Stock symbol
APLS
Transactions as of
Apr 20, 2022
Transactions value $
-$259,070
Form type
4
Date filed
4/22/2022, 05:35 PM
Previous filing
Feb 14, 2022
Next filing
Jun 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $109K +7K +24.58% $15.52 35.5K Apr 20, 2022 Direct F1
transaction APLS Common Stock Sale -$368K -7K -19.73% $52.53 28.5K Apr 20, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -7K -16.67% $0.00 35K Apr 20, 2022 Common Stock 7K $15.52 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from an established 10B5-1 trading plan.
F2 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.